Examining the oleoylethanolamide supplement effects on glycemic status, oxidative stress, inflammation, and anti-mullerian hormone in polycystic ovary syndrome.

Publisher: BioMed Central Country of Publication: England NLM ID: 101474849 Publication Model: Electronic Cited Medium: Internet ISSN: 1757-2215 (Electronic) Linking ISSN: 17572215 NLM ISO Abbreviation: J Ovarian Res Subsets: MEDLINE

Original Publication: [London] : BioMed Central, c2008-

Polycystic Ovary Syndrome*/drug therapy ; Polycystic Ovary Syndrome*/blood ; Endocannabinoids* ; Oxidative Stress*/drug effects ; Oleic Acids*/therapeutic use ; Oleic Acids*/pharmacology ; Inflammation*/drug therapy ; Inflammation*/blood ; Dietary Supplements* ; Blood Glucose*/drug effects ; Blood Glucose*/metabolism ; Anti-Mullerian Hormone*/blood; Humans ; Female ; Adult ; Young Adult ; Insulin Resistance ; Double-Blind Method ; Antioxidants/pharmacology ; Antioxidants/therapeutic use

Objective: This clinical trial was designed and conducted due to the anti-inflammatory potential of Oleoylethanolamide (OEA) to examine the effect of OEA supplement on glycemic status, oxidative stress, inflammatory factors, and anti-Mullerian hormone (AMH) in women with polycystic ovary syndrome (PCOS).
Method: This study was a randomized clinical trial, double-blinded, placebo-controlled that was carried out on 90 women with PCOS. Patients were divided into two groups: receiving an OEA supplement (n = 45) or a placebo (n = 45). The intervention group received 125 mg/day OEA and the placebo group received the wheat flour for 8 weeks. Demographic data were collected through questionnaires. Fasting blood sugar (FBS), insulin resistance (IR), total antioxidant capacity (TAC), malondialdehyde (MDA), C-reactive protein (CRP), tumor necrosis factor-alpha (TNF-α), and AMH were measured before and after the study.
Results: Data analysis of food recall and physical activity questionnaires, showed no significant differences between the two groups (p > 0.05). Biochemical factors including glycemic status, MDA, inflammatory factors, and AMH decreased significantly (p < 0.05). TAC increased remarkably (p < 0.05) in comparison between the two groups, after the intervention.
Conclusion: OEA supplement with anti-inflammatory characteristics could be efficient independent of diet changes and physical activity in improving disrupted biochemical factors, so both supplementation or food resources of this fatty acid could be considered as a compensatory remedy in patients with PCOS.
Trial Registration: This study was retrospectively (09-01-2022) registered in the Iranian website ( www.irct.ir ) for registration of clinical trials (IRCT20141025019669N20).
(© 2024. The Author(s).)

J Pharmacol Sci. 2015 Mar;127(3):244-50. (PMID: 25837920)
J Clin Endocrinol Metab. 2001 Aug;86(8):3761-7. (PMID: 11502808)
Adv Pharm Bull. 2018 Aug;8(3):479-487. (PMID: 30276145)
Int J Prev Med. 2019 May 17;10:86. (PMID: 31198521)
Diabetol Metab Syndr. 2022 Jun 3;14(1):77. (PMID: 35659064)
J Obstet Gynaecol Res. 2022 May;48(5):1212-1221. (PMID: 35293068)
Front Pharmacol. 2017 Nov 07;8:798. (PMID: 29163178)
Hum Reprod Update. 2013 May-Jun;19(3):268-88. (PMID: 23303572)
World J Cardiol. 2013 Jun 26;5(6):164-74. (PMID: 23802046)
Australas J Ultrasound Med. 2018 May 17;21(2):59-60. (PMID: 34760503)
Int J Mol Sci. 2022 Jan 06;23(2):. (PMID: 35054768)
Diagnostics (Basel). 2023 Feb 27;13(5):. (PMID: 36900051)
J Trace Elem Med Biol. 2022 May;71:126945. (PMID: 35183882)
Front Endocrinol (Lausanne). 2020 Sep 09;11:641. (PMID: 33013710)
Metabolites. 2021 Dec 14;11(12):. (PMID: 34940628)
JAMA Intern Med. 2018 Aug 1;178(8):1098-1103. (PMID: 29971406)
J Hum Reprod Sci. 2020 Oct-Dec;13(4):261-271. (PMID: 33627974)
Int J Mol Sci. 2021 Feb 07;22(4):. (PMID: 33562271)
Sci Rep. 2016 Oct 10;6:34611. (PMID: 27721381)
Nutrients. 2020 May 28;12(6):. (PMID: 32481491)
Int J Behav Nutr Phys Act. 2007 Dec 03;4:62. (PMID: 18053188)
Nutrients. 2021 Oct 08;13(10):. (PMID: 34684528)
Appetite. 2018 Sep 1;128:44-49. (PMID: 29787831)
Metabolism. 2010 Jun;59(6):824-30. (PMID: 20004425)
Prog Lipid Res. 2017 Jul;67:1-15. (PMID: 28389247)
J Biol Chem. 2004 Jul 2;279(27):27849-54. (PMID: 15123613)
Front Pharmacol. 2021 Jan 18;11:605065. (PMID: 33536915)
Pharmacol Res. 2020 Jun;156:104770. (PMID: 32217148)
Cardiovasc Diabetol. 2019 Oct 1;18(1):127. (PMID: 31575375)
Antioxidants (Basel). 2021 Jul 05;10(7):. (PMID: 34356308)
Asian J Sports Med. 2011 Jun;2(2):106-16. (PMID: 22375226)
Int J Endocrinol. 2015;2015:508409. (PMID: 26136779)
Hum Reprod. 2018 Sep 1;33(9):1602-1618. (PMID: 30052961)
Iran J Reprod Med. 2015 Oct;13(10):591-604. (PMID: 26644787)
Cell Death Dis. 2018 Jan 25;9(2):119. (PMID: 29371661)
Int J Physiol Pathophysiol Pharmacol. 2019 Jun 15;11(3):45-63. (PMID: 31333808)
Lipids Health Dis. 2015 Sep 29;14:121. (PMID: 26415887)

IR.QUMS.REC.1400.370 Qazvin University of Medical Sciences

Keywords: Anti-mullerian hormone; Glycemic status; Inflammation; Oleoylethanolamide; Oxidative stress; Polycystic ovary syndrome

0 (Endocannabinoids)
1HI5J9N8E6 (oleoylethanolamide)
0 (Oleic Acids)
0 (Blood Glucose)
80497-65-0 (Anti-Mullerian Hormone)
0 (Antioxidants)

Date Created: 20240522 Date Completed: 20240523 Latest Revision: 20240710

20250114

PMC11110282

10.1186/s13048-024-01432-1

38778429